North America Brain Cancer Diagnostic Market
Taille du marché en milliards USD
TCAC : %
Période de prévision |
2024 –2030 |
Taille du marché (année de référence) |
|
Taille du marché (année de prévision) |
Dollars américains 2,880.20 |
TCAC |
|
Principaux acteurs du marché |
>Marché nord-américain du diagnostic du cancer du cerveau, par type de test (test d'imagerie, biopsie, ponction lombaire, test moléculaire, électroencéphalographie et autres), type de cancer ( neurinome acoustique , astrocytomes, glioblastome multiforme, méningiomes, oligodendrogliome et autres), groupe d'âge (moins de 21 ans, 21-34, 35-65 ans et 65 ans et plus), utilisateur final (hôpitaux, cliniques spécialisées, centres de diagnostic et instituts de recherche, centres de chirurgie ambulatoire et autres), tendances de l'industrie et prévisions jusqu'en 2030.
Analyse et taille du marché du diagnostic du cancer du cerveau en Amérique du Nord
L'un des principaux facteurs à l'origine de la croissance du marché du diagnostic du cancer du cerveau est l'augmentation des cas de cancer du cerveau dans le monde. Les recherches continues sur les essais cliniques menées par plusieurs entreprises pour un meilleur traitement conduisent à l'expansion du marché. Le marché est également influencé par la sensibilisation croissante au diagnostic précoce du cancer du cerveau et aux innovations dans l'administration de médicaments aux cellules cancéreuses du cerveau. Cependant, le coût élevé associé au diagnostic et au traitement du cancer du cerveau, le diagnostic tardif du cancer du cerveau entraînant un mauvais pronostic et les effets secondaires des médicaments et des thérapies de traitement constituent un facteur restrictif pour le marché nord-américain du diagnostic du cancer du cerveau au cours de la période de prévision.
D’un autre côté, l’augmentation des investissements et du financement des acteurs émergents, les initiatives gouvernementales en matière de diagnostic du cancer et l’augmentation des dépenses de santé constituent des opportunités pour la croissance du marché. Cependant, les exigences réglementaires strictes pour les produits de diagnostic et les obstacles opérationnels rencontrés dans la réalisation des tests de diagnostic créent des défis pour le marché nord-américain du diagnostic du cancer du cerveau.
La demande de produits de diagnostic du cancer du cerveau va augmenter en Amérique du Nord, grâce à l'amélioration des techniques d'imagerie. Diverses entreprises prennent des initiatives qui conduisent progressivement à la croissance du marché.
Le marché du diagnostic du cancer du cerveau en Amérique du Nord devrait connaître une croissance du marché au cours de la période de prévision de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 19,3 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 2 880,20 millions USD d'ici 2030.
Rapport métrique |
Détails |
Période de prévision |
2023 à 2030 |
Année de base |
2022 |
Années historiques |
2021 (personnalisable pour 2020-2016) |
Unités quantitatives |
Chiffre d'affaires en millions USD |
Segments couverts |
Type de test (test d'imagerie, biopsie, ponction lombaire, test moléculaire, électroencéphalographie et autres), type de cancer (neurinome acoustique, astrocytomes, glioblastome multiforme, méningiomes, oligodendrogliome et autres), groupe d'âge (moins de 21 ans, 21-34, 35-65 ans et 65 ans et plus), utilisateur final (hôpitaux, cliniques spécialisées, centres de diagnostic et instituts de recherche, centres de chirurgie ambulatoire et autres). |
Pays couverts |
États-Unis, Canada et Mexique |
Acteurs du marché couverts |
NIHON KOHDEN CORPORATION., Canon Inc., FUJIFILM Holdings Corporation, Neusoft Corporation, GE HealthCare, Koninklijke Philips N.V., BD, and FONAR Corp., among others |
Market Definition
Brain cancer is an overgrowth of cells in the brain that forms masses called tumors. It is a brain disorder in which cancer cells (malignant cells) arise in the brain tissue. Cancer cells multiply to produce a mass of cancer tissue (tumor) that interferes with brain functions such as muscle control, sensation, memory, and other body functions. Cancer cells that arise from brain tissue are called primary brain tumors, while tumors that spread from other body parts to the brain are called metastatic or secondary brain tumors.
Primary brain tumors can develop from various brain tissues (for example, glial cells, astrocytes, and other brain cell types). Metastatic brain cancer is caused by the spread of cancer cells from a body organ to the brain.
North America Brain Cancer Diagnostic Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising Cases of Brain Cancer Worldwide
Cancer that develops elsewhere in the body & then spreads into the brain is called a secondary brain tumor or brain metastasis. There are various cancers that can metastasize into the brain, such as breast cancer, lung cancer, colon cancer and kidney cancer. Brain cancer cells generally do not spread beyond the brain. Rather, they have the capacity to travel short distances within the brain. Genetic links inherited through family ancestors, chemical exposure to certain industrial chemicals or solvents, compromised immune system, and previous radiation treatments can be some of the major causes of brain cancer.
Brain cancer cases are rising worldwide. In 2019, as per the National Cancer Institute report, there were an estimated 176,566 people found living with brain & other nervous system cancer in the United States. In addition, based on 2017-2019 data, it has been predicted that approximately 0.6 percent of men & women will be diagnosed with brain and other nervous system cancer at some point during their lifetime.
- Rising awareness of the early diagnosis of brain cancer
Brain cancer awareness month is nationally recognized in the United States during the month of May. This awareness month focuses on bringing together the brain tumor community to increase awareness among the patient population.
Brain cancer is not a common type of cancer like other types. However, the need for new & innovative ways to treat brain cancer is more important. As per research studies, 1.4 million patients worldwide are suffering from malignant brain tumors & another 2, 56,000 people will be diagnosed with a malignant brain tumor by the end of the year.
The importance of patient care, education & cancer research is becoming more apparent due to the impact of COVID-19 worldwide. Considering the future perspectives, there is still more groundwork to be done to discover new drugs & effective approaches for brain cancer patients. Brain cancer awareness month is a movement that is fully dedicated to these efforts and even in the midst of a pandemic.
Opportunities
- Increasing investment and funding by emerging players
The market for brain cancer is huge, and the rising number of the population affected by this disease is attracting other players to work in the diagnostic field for this disease. Diagnosis of brain cancer in the early stage is a tedious task but can be possible with the new product line for the diagnosis of disease.
The industry offers numerous growth opportunities. Thus, a number of start-ups providing innovative products and technologies have been entering the market. Many new companies and start-ups are looking forward to the field of brain cancer. They are trying to make business expansion and increase the distribution of their newly marketed product. Some of the company are listed below and is expected to act as an opportunity for a brain cancer diagnosis.
- Government initiatives toward cancer diagnostics
The government plays a major role while taking the initiative for cancer diseases because cancer is a leading disease across the globe. Cancer has increased very briskly in people in past decades. There were 9,555,027 cases of deaths attributable to North America cancers in 2018, of which 241,037 (2.71%) belonged to brain cancers.
The government all around the globe is actively engaged in taking several initiatives towards cancer, specifically brain cancer diagnostics, in order to increase awareness among the people regarding the cancerous disease. Government and Nongovernment organizations funded 57% of therapy-oriented biology and drug development, with 7% to prevention and 13% to early detection, diagnosis and prognosis of cancer disease. These government initiatives towards cancer diagnostics are boosting the demand of the market.
Restraints/Challenges
- High cost associated with diagnosis & treatment for brain cancer
The brain is the most important part of our body, the organ which generates our memories and emotions, as well as containing our skills and expertise. Therefore, cancer of the brain is uniquely destructive. The changes a brain tumor can cause in cognition, behavior and personality result in high economic costs, which are borne by individuals, health systems (direct medical costs) and the wider public purse (direct non-medical costs and indirect costs).
The average cost of brain tumor surgery in western countries is very high. The costs associated with each type of treatment will vary depending on the specific procedure, location, and tumor severity. A study published in the journal Cancer found that brain cancer patients and their families bore a significantly higher economic burden than those affected by other types of cancer. Brain cancer patients had the highest indirect costs, at an average of USD 64,790 per year. Hence, the high cost associated with the diagnosis & treatment of brain cancer may restrain the market growth.
- Operational Barriers Faced in Conducting Diagnostics Tests
Recent advances in the field of brain cancer diagnostics may be related to the kits, instruments, reagents, control or any other. It is not easy to change the adaptability of healthcare professionals with advancement. In order to make the structural decisions and précised results in diagnostics, organizations need to conduct a training session for the healthcare professionals to overcome and avoid errors in diagnosis.
Rural, developing, and low-income countries in the different regions do not have enough infrastructure to maintain the new kits and for the sample storage as well. This is because of the limited supply of electricity and lack and education and awareness among healthcare professionals in the handling of new kits and reagents. This leads to errors in the diagnosis results and can lead to certain deaths, and can become a threat to the carrier of the individual performing the test.
These barriers related to conducting the cancer diagnostics test may affect the life of the populations. This is one of the most difficult parts to overcome with respect to low-income countries. Thus, this is affecting the diagnostics community and acting as a challenge for the North America brain cancer diagnostic market.
Post-COVID-19 Impact on the North America Brain Cancer Diagnostic Market
The COVID-19 pandemic had a great impact on the brain cancer diagnostics and surgical industries. Trade groups in the cancer diagnostic products sector claim that the North America supply chain for diagnostic products has been significantly damaged, impacting end-user consumption of the brain cancer diagnostic market. Sales of diagnostics products in the first quarter of 2020 were significantly delayed due to logistical and transportation issues. On the demand side, the market is increasing as people have to get diagnosed after the lockdown scenario. The situation needs to be taken into consideration, and emergency diagnostics need to be done. Furthermore, on the supply side, the growth of the market is on a negative scale. This is due to the lockdown situations in many countries manufacturing diagnostic, operating and cancer care instruments.
The supply of diagnostic products has suffered a massive hit due to the North America pandemic of COVID-19. This reduction in supply is mainly due to various quarantine policies adopted by countries worldwide. This, along with the restrictions of movement and labor reduction, are the major reasons for a decreasing trend in the supply market of diagnostic instrument tracking systems. This has affected the quality and efficacy of medical devices a great deal. The existing product exportation policies of many countries have misbalanced the supply to demand ratio. Reduction in the headcount of the labor force due to COVID-19 affliction is another factor contributing to the reduced supply of brain cancer diagnostics products.
Recent Developments
- In November 2022, Siemens Healthcare GmbH has presented its two latest magnetic resonance tomographs designed for clinical and scientific use. Due to their high field strengths and strong gradient performance, both scanners will be optimal for detecting the finest structures in the body more clearly.
- In November 2022, BD has announced to grant USD 652,000 to Valley-Mount Sinai Comprehensive Cancer Care to increase diversity, equity and inclusion in cancer clinical trials.
North America Brain Cancer Diagnostic Market Scope
The North America brain cancer diagnostic market is segmented into test type, cancer type, age group and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Test Type
- Imaging Tests
- Biopsy
- Lumbar Puncture
- Molecular Testing
- Electroencephalography (EEG)
- Others
On the basis of test type, the North America brain cancer diagnostic market is segmented into imaging tests, biopsy, lumber puncture, molecular testing, electroencephalography (EEG), and others.
Cancer Type
- Acoustic Neuroma
- Astrocytomas
- Glioblastoma Multiforme
- Meningiomas
- Oligodendroglioma
- Others
On the basis of cancer type, the North America brain cancer diagnostic market is segmented into acoustic neuroma, astrocytomas, glioblastoma multiforme, meningiomas, oligodendroglioma, and others.
Age Group
- Below 21
- 21-35
- 35-65
- 65 and above
On the basis of age group, the North America brain cancer diagnostic market is segmented into below 21, 21-34, 35-65 and 65 and above.
End User
- Hospitals
- Specialty clinics
- Diagnostic centers and research institutes
- Ambulatory surgical centers
- Others
On the basis of end user, the North America brain cancer diagnostic market is segmented into hospitals, specialty clinics, diagnostic centers, research institutes, ambulatory surgical centers, and others.
North America Brain Cancer Diagnostic Market Regional Analysis/Insights
The North America brain cancer diagnostic market is analyzed, and market size insights and trends are provided by country, test type, cancer type, age group, and end user.
Le marché mondial du diagnostic du cancer du cerveau comprend les États-Unis, le Canada et le Mexique.
- En 2023, les États-Unis devraient dominer le marché nord-américain du diagnostic du cancer du cerveau en raison de la sensibilisation croissante des consommateurs aux avantages d'un diagnostic du cancer du cerveau. Une augmentation de la demande de produits de diagnostic du cancer du cerveau et une augmentation des activités de recherche et développement dans l'industrie devraient également stimuler le marché au cours de la période prévue.
Analyse du paysage concurrentiel et des parts de marché du diagnostic du cancer du cerveau en Amérique du Nord
Le paysage concurrentiel du marché du diagnostic du cancer du cerveau fournit des détails par concurrents. Les détails inclus sont un aperçu de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Amérique du Nord, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que les entreprises se concentrant sur le marché du diagnostic du cancer du cerveau en Amérique du Nord.
Certains des principaux acteurs opérant sur ce marché sont NIHON KOHDEN CORPORATION, Canon Inc., FUJIFILM Holdings Corporation, Neusoft Corporation, GE HealthCare, Koninklijke Philips NV, BD et FONAR Corp., entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EPIDEMIOLOGY
6 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT
7 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS
7.1 REGULATORY SCENARIO IN THE U.S
7.2 REGULATORY SCENARIO IN AUSTRALIA
7.3 REGULATORY SCENARIO IN JAPAN
7.4 REGULATORY SCENARIO IN CHINA
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE
8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER
8.1.3 IMPROVED IMAGING TECHNIQUES
8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS
8.2 RESTRAINTS
8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER
8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES
8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS
8.3 OPPORTUNITIES
8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS
8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC
8.3.3 RISING HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS
8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS
9 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING TEST
9.2.1 CT SCAN
9.2.2 MRI
9.2.3 PET
9.2.4 OTHERS
9.3 MOLECULAR TESTING
9.4 ELECTROENCEPHALOGRAPHY (EEG)
9.5 LUMBAR PUNCTURE
9.6 BIOPSY
9.6.1 OPEN BIOPSY
9.6.2 STEREOTACTIC BIOPSY
9.6.3 NEEDLE BIOPSY
9.6.4 NEUROENDOSCOPY
9.7 OTHERS
10 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 GLIOBLASTOMA MULTIFORME
10.3 MENINGIOMAS
10.4 ASTROCYTOMAS
10.5 ACOUSTIC NEUROMA
10.6 OLIGODENDROGLIOMA
10.7 OLIGODENDROGLIOMA
10.8 OTHERS
11 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 35-65
11.3 65 AND ABOVE
11.4 BELOW 21
11.5 21-34
12 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 SPECIALTY CLINICS
12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES
12.5 AMBULATORY SURGICAL CENTERS
12.6 OTHERS
13 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
14 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE
16.1 KONINKLIJKE PHILIPS N.V.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 CANON INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 SIEMENS HEALTHCARE GMBH
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 BD
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 NIHON KOHDEN CORPORATION.
16.5.1 COMPANY SNAPSHOT
16.5.2 RECENT FINANCIALS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 BIOCEPT, INC.
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 BIOMIND
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 CEREBRAL DIAGNOSTIC
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 DXCOVER LIMITED
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 FONAR CORP.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 FUJIFILM CORPORATION
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 GE HEALTHCARE.
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 HITACHI, LTD.
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 MINFOUND MEDICAL SYSTEMS CO.,
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 NANTOMICS.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 NEUSOFT CORPORATION
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 SEQUOIA HEALTHCARE.
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
16.18 STERNMED GMBH
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 THERMO FISHER SCIENTIFIC INC.
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENT
16.2 TIME MEDICAL HOLDING.
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
Liste des tableaux
TABLE 1 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA MOLECULAR TESTING IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA ELECTROENCEPHALOGRAPHY (EEG) IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA LUMBAR PUNCTURE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA GLIOBLASTOMA MULTIFORME IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA MENINGIOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA ASTROCYTOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA ACOUSTIC NEUROMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA OLIGODENDROGLIOMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA 35-65 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA 65 AND ABOVE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA BELOW 21 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA 21-34 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA HOSPITALS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA SPECIALTY CLINICS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA DIAGNOSTIC CENTERS & RESEARCH INSTITUTES IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 35 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 36 U.S. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 37 U.S. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 38 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 39 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 40 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 41 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 42 CANADA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 43 CANADA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 44 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 45 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 46 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 47 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 48 MEXICO IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 49 MEXICO BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 50 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 51 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 52 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: DBMR POSITION GRID
FIGURE 8 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 RISING CASES OF BRAIN CANCER WORLDWIDE & IMPROVED IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET
FIGURE 14 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, 2022
FIGURE 15 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, 2022
FIGURE 19 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2022
FIGURE 23 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 26 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2022
FIGURE 27 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)
FIGURE 31 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)
FIGURE 32 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)
FIGURE 33 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)
FIGURE 34 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)
FIGURE 35 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.